Tardo Antonio Maria, Irace Concetta, Del Baldo Francesca, Foglia Armando, Fracassi Federico
Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, 40064 Bologna, Italy.
Department of Health Science, University Magna Græcia, 88100 Catanzaro, Italy.
Animals (Basel). 2022 Mar 29;12(7):860. doi: 10.3390/ani12070860.
The novel Eversense XL continuous glucose monitoring system (Senseonics, Inc., Germantown, Maryland) has recently been developed for monitoring diabetes in humans. The sensor is fully implanted and has a functional life of up to 180 days. The present study describes the use of Eversense XL in three diabetic dogs (DD) with good glycemic control managed by motivated owners. The insertion and use of the device were straightforward and well tolerated by the dogs. During the wearing period, some device-related drawbacks, such as sensor dislocation and daily calibrations, were reported. A good correlation between the glucose values measured by the Eversense XL and those obtained with two commercially available devices, previously validated for use in DD, was found (r = 0.85 and r = 0.81, respectively). The life of the sensor was 180 days in two of the DD and provided high satisfaction. This innovative device might be considered a future alternative for home glucose monitoring in DD.
新型Eversense XL连续血糖监测系统（Senseonics公司，马里兰州日耳曼敦）最近已开发用于监测人类糖尿病。该传感器完全植入体内，功能寿命长达180天。本研究描述了Eversense XL在三只血糖控制良好的糖尿病犬（DD）中的使用情况，这些犬由积极主动的主人管理。该设备的插入和使用操作简单，犬只耐受性良好。在佩戴期间，报告了一些与设备相关的缺点，如传感器脱位和每日校准。发现Eversense XL测量的血糖值与两种先前经验证可用于DD的市售设备获得的血糖值之间具有良好的相关性（分别为r = 0.85和r = 0.81）。两只DD的传感器使用寿命为180天，并提供了高度满意度。这种创新设备可能被视为未来DD家庭血糖监测的一种替代方案。
